Healthpeak Properties (DOC) Q4 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2025 earnings summary
9 Jul, 2026Executive summary
Finished 2025 with earnings in line with original guidance, significant transaction activity, and announced the planned IPO of Janus Living to unlock value in the senior housing portfolio.
Outpatient Medical now over 50% of portfolio income, benefiting from merger synergies and sector tailwinds.
Executed a $1 billion capital recycling plan, including asset sales, recapitalizations, and loan repayments to fund higher-growth opportunities.
Enhanced technology and innovation initiatives, including hiring a Head of Enterprise Innovation and rolling out an agentic operating system.
Strengthened leadership team with key hires in innovation, finance, legal, and investments.
Financial highlights
Q4 2025 FFO as adjusted: $0.47/share; AFFO: $0.40/share; same-store cash NOI growth: 3.9%.
Full year FFO as adjusted: $1.84/share; AFFO: $1.69/share; same-store cash NOI growth: 4%.
Outpatient Medical: 4.9M sq ft leased, 5% cash re-leasing spreads, 91% occupancy, 3.9% same-store growth.
Lab: 1.5% same-store growth, 77% occupancy, 1.5M sq ft leased, 5% re-leasing spreads.
Senior Housing/Life Plan: 12.6% same-store growth for 2025, 16.7% in Q4.
Outlook and guidance
2026 FFO as adjusted guidance: $1.70–$1.74/share; same-store NOI growth forecast: -1% to +1%.
Outpatient Medical: 2–3% growth; Lab: -5% to -10%; Senior Housing: 8–12%.
Earnings reduction driven by lab occupancy loss; Outpatient Medical and Senior Housing expected to offset some headwinds.
$1B+ of asset sales, recapitalizations, and loan repayments planned for 2026.
Life science real estate fundamentals expected to be at or near an inflection point, with gradual recovery anticipated.
Latest events from Healthpeak Properties
- Earnings and guidance rose on Janus Living IPO, senior housing gains, and major JV proceeds.DOC
Q2 2026 - All director nominees and proposals passed with a 91% quorum and no shareholder questions.DOC
AGM 2026 - 2026 guidance raised after Janus Living IPO, strong leasing, and robust capital actions.DOC
Q1 2026 - Key votes include board elections, executive pay approval, and auditor ratification for 2026.DOC
Proxy Filing - 2025 saw strong results, board refreshment, and enhanced ESG, with key votes on directors, pay, and auditor.DOC
Proxy Filing - Janus Living IPO and operational efficiencies position Healthpeak for growth in core healthcare real estate.DOC
Citi’s Miami Global Property CEO Conference 2026 - Janus Living IPO, $600M biotech campus acquisition, and $1B capital recycling drive growth.DOC
Investor presentation - Q2 2025 saw strong NOI growth, higher AFFO/FFO, and robust liquidity.DOC
Q2 2025 - Q1 2025 delivered strong earnings growth, robust leasing, and reaffirmed 2025 guidance.DOC
Q1 2025